GRAIL, Inc.

GRAIL, Inc. Stock Forecast & Price Prediction

Live GRAIL, Inc. Stock (GRAL) Price
$15.93

0

Ratings

  • Buy 0
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$15.93

P/E Ratio

-0.38

Volume Traded Today

$2.8M

Dividend

Dividends not available for GRAL

52 Week High/low

23.36/12.33

GRAIL, Inc. Market Cap

$449.6M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $GRAL ๐Ÿ›‘

Before you buy GRAL you'll want to see this list of ten stocks that have huge potential. Want to see if GRAL made the cut? Enter your email below

GRAL Summary

Based on ratings from 0 stock analysts, the GRAIL, Inc. stock price is expected to decrease by 100% in 12 months. This is calculated by using the average 12-month stock price forecast for GRAIL, Inc.. The lowest target is $ and the highest is $. Please note analyst price targets are not guaranteed and could be missed completely.

GRAL Analyst Ratings

About 0 Wall Street analysts have assignedGRAL 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect GRAIL, Inc. to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on GRAL. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

GRAL stock forecast by analyst

These are the latest 20 analyst ratings of GRAL.

Analyst/Firm

Rating

Price Target

Change

Date

Subbu Nambi
Guggenheim

Neutral


Initiates

Oct 17, 2024

GRAL Company Information

What They Do: Develops technologies for early cancer detection.

Business Model: The company generates revenue by offering innovative cancer screening and diagnostic tests, primarily targeting asymptomatic individuals aged 50 and above through its Galleri test. Additionally, it focuses on developing tools that assist in the diagnostic process for suspected cancer cases, enhancing the overall efficiency and accuracy of cancer diagnostics.

Other Information: Founded in 2015 and based in Menlo Park, California, GRAIL, Inc. operates as a former subsidiary of Illumina, Inc., benefiting from its parent company's expertise in genomics and biotechnology.
GRAL
GRAIL, Inc. (GRAL)

When did it IPO

2024

Staff Count

1,360

Country

United States

Sector/Industry

Healthcare/Diagnostics & Research

CEO

Mr. Robert P. Ragusa

Market Cap

$449.6M

GRAIL, Inc. (GRAL) Financial Data

In 2023, GRAL generated $93.1M in revenue, which was a increase of 67.61% from the previous year. This can be seen as a signal that GRAL's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

N/A

Revenue From 2021

N/A

0.00 %
From Previous Year

Revenue From 2022

$55.6M

0.00 %
From Previous Year

Revenue From 2023

$93.1M

67.61 %
From Previous Year
  • Revenue TTM $109.7M
  • Operating Margin TTM -689.3%
  • Gross profit TTM $-95,611,000
  • Return on assets TTM -32.8%
  • Return on equity TTM -35.2%
  • Profit Margin -102.7%
  • Book Value Per Share 86.80%
  • Market capitalisation $449.6M
  • Revenue for 2021 N/A
  • Revenue for 2022 $55.6M
  • Revenue for 2023 $93.1M
  • EPS this year (TTM) $-87.00

GRAIL, Inc. (GRAL) Latest News

News Image

Tue, 12 Nov 2024

Sentiment - NEUTRAL

Source - PRNewsWire

Summary - GRAIL, Inc. reported a 52% YoY revenue increase to $25.4 million for Q3 2024, with over 250,000 Galleri tests sold. The company has a cash balance of $853.6 million, funding operations through 2028.

Why It Matters - Galleri's 52% revenue growth and significant test sales indicate strong market demand. A cash balance of $853.6 million ensures financial stability, enhancing growth potential and investor confidence.

News Image

Mon, 04 Nov 2024

Sentiment - NEUTRAL

Source - PRNewsWire

Summary - GRAIL, Inc. (Nasdaq: GRAL) will present at the Canaccord Genuity MedTech Forum in New York on Nov. 21 at 11:00 a.m., focusing on early cancer detection.

Why It Matters - GRAIL's presentation at a prominent healthcare forum could signal its growth potential and attract investor interest, influencing stock performance and market perception.

News Image

Tue, 29 Oct 2024

Sentiment - NEUTRAL

Source - PRNewsWire

Summary - GRAIL, Inc. (Nasdaq: GRAL) will release its Q3 2024 financial results on Nov. 12, 2024, after market close.

Why It Matters - GRAIL's Q3 2024 financial results announcement could impact stock performance, reflecting its operational progress and potential market reception of its cancer detection technology.

News Image

Mon, 21 Oct 2024

Sentiment - NEUTRAL

Source - PRNewsWire

Summary - GRAIL, Inc. has appointed Sarah Krevans to its Board of Directors, effective immediately, as part of its focus on early cancer detection.

Why It Matters - Sarah Krevans joining GRAIL's Board may signal strategic growth and enhanced leadership, potentially boosting investor confidence and impacting stock performance positively.

News Image

Wed, 23 Oct 2024

Sentiment - NEUTRAL

Source - PRNewsWire

Summary - GRAIL, Inc. announced early results from the REFLECTION study, evaluating the Galleriยฎ multi-cancer early detection test in diverse clinical settings, focusing on real-world effectiveness.

Why It Matters - Positive results from the REFLECTION study could boost GRAIL's stock value, indicating strong demand for the Galleriยฎ test and enhancing its market position in early cancer detection.

News Image

Sun, 13 Oct 2024

Sentiment - NEGATIVE

Source - 24/7 Wall Street

Summary - Insider buying has significantly decreased ahead of the third-quarter earnings reporting season, indicating potential caution among executives.

Why It Matters - Insider buying trends can indicate company confidence; a slowdown may signal caution or uncertainty about forthcoming earnings, potentially affecting stock performance.

...

GRAL Frequently asked questions

The highest forecasted price for GRAL is $ from Subbu Nambi at Guggenheim.

The lowest forecasted price for GRAL is $ from Subbu Nambi from Guggenheim

The GRAL analyst ratings consensus are 0 buy ratings, 0 hold ratings, and 0 sell ratings.